Indivior Pharmaceuticals, Inc
Held by 9 tracked managers as of Q2 2026 · CUSIP ⓘCUSIP: A 9-character ID for one specific security - one share class of one company, or one bond. Tickers can change and can mean different things in different countries; a CUSIP always identifies exactly the same security, which is why filings use it. Guide 868459108 · Sector ⓘGICS sectors: The 11-sector system most investors know (Global Industry Classification Standard): Technology, Health Care, Financials and so on. This site assigns each company a GICS-style sector from its SIC code, with a few hand corrections, so sector pages match the names investors expect. Guide
Educational and informational only, not personalized investment advice. Based on public filings that may be delayed or contain errors; verify with the original filings. Disclaimer
Tracked capital in this stock
Total value held (area) and number of managers (line). Dips can mean a large holder filed that quarter confidentially (e.g. Norges Bank in Q1/Q3).
Aggregate buying and selling
Net share change reported each quarter
Who owns SUPN?
🔒 The 'who added and who trimmed' chart is a Plus feature
You're viewing the Free plan. Upgrade to unlock The 'who added and who trimmed' chart — every paid plan starts with a 7-day free trial, and you can cancel in two clicks.
Who owns SUPN? — Q2 2026
Holders ranked by position size, with each one's quarter-over-quarter change.
Column filters
| # | Manager | Fund | Shares | Value ↓ | % of their portfolio | QoQ | Δ shares | Δ shares % | Est. Δ value ⓘChange in shares × this quarter's price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Israel Englander | Millennium Management | 3.85M | $179.21M | 0.1% | Added | +537.2K | +16.2% | +$24.99M |
| 2 | Jim Simons | Renaissance Technologies | 1.48M | $68.75M | 0.1% | Reduced | -227.0K | -13.3% | -$10.56M |
| 3 | Ken Griffin | Citadel Advisors | 1.37M | $63.90M | 0.0% | Reduced | -119.5K | -8.0% | -$5.56M |
| 4 | Two Sigma | Two Sigma Investments | 1.18M | $55.09M | 0.0% | Added | +913.1K | +336.7% | +$42.47M |
| 5 | David Shaw | D.E. Shaw & Co. | 767.67K | $35.70M | 0.0% | Added | +145.2K | +23.3% | +$6.75M |
| 6 | Third Avenue | Third Avenue Management | 152.72K | $7.10M | 1.1% | Held | 0 | 0.0% | $0 |
| 7 | Chuck Royce | Royce & Associates | 39.52K | $1.84M | 0.0% | Reduced | -190.4K | -82.8% | -$8.86M |
| 8 | Bridgeway | Bridgeway Capital Management | 18.00K | $837.18K | 0.0% | Reduced | -30.0K | -62.5% | -$1.40M |
| 9 | LSV Asset Management | LSV Asset Management | 6.10K | $284.00K | 0.0% | Held | 0 | 0.0% | $0 |
Column filters
| Manager | Fund | Shares sold | Value last quarter ↓ |
|---|---|---|---|
| Steve Cohen | Point72 Asset Management | -1.3M | $68.16M |
Politician trades
Column filters
| Politician | Date | Ticker | Asset | Type | Reported range ⓘThe dollar range the politician reported. Exact amounts are not disclosed. | Est. size ⓘOur estimate only: the midpoint of the reported range. | Owner | Account ⓘSubholding Of: the account the trade was in, as named on the report (e.g. an IRA or a brokerage account). The same stock bought on the same day in different accounts is a separate trade in each account. | Filed ↓ | Filing delay ⓘDays between the trade and the report. Over 45 days is late under the STOCK Act. | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gil Cisneros Politician | Mar 3, 2026 | SUPN | Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Apr 7, 2026 | 35 days | PTR ↗ |
| Gil Cisneros Politician | Dec 11, 2025 | SUPN | Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Jan 12, 2026 | 32 days | PTR ↗ |
| Gil Cisneros Politician | Oct 9, 2025 | SUPN | Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) [ST] | Sale (partial) | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Nov 18, 2025 | 40 days | PTR ↗ |
| Gil Cisneros Politician | Mar 24, 2025 | SUPN | Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | 150 Main Street Trust > Bank of America | Apr 7, 2025 | 14 days | PTR ↗ |